Pharmacokinetics and pharmacodynamics in the treatment of cutaneous leishmaniasis – challenges and opportunities. Issue 4 (7th January 2021)

• Record Type: Journal Article
• Authors: Van Bocxlaer, Katrien; Croft, Simon L.
• Is Part Of: RSC medicinal chemistry. Volume 12:Issue 4(2021)
• Page Start: 472
• Page End: 482
• Publication Date: 2021-01-07
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.1039/d0md00343c
• Languages: English
• ISSNs: 2632-8682

Abstract

Abstract : Important pharmacokinetic and -dynamic parameters for the drug discovery and development of new treatments for cutaneous leishmaniasis. Abstract : Pharmacological efficacy is obtained when adequate concentrations of a potent drug reach the target site. In cutaneous leishmaniasis, a heterogeneous disease characterised by a variety of skin manifestations from simple nodules, skin discoloration, plaques to extensive disseminated forms, the parasites are found in the dermal layers of the skin. Treatment thus involves the release of the active compound from the formulation (administered either topically or systemically), it's permeation into the skin, accumulation by the local macrophages and further transport into the phagolysosome of the macrophage. The pharmacodynamic activity of a drug against the parasite is relatively straight forward to evaluate both in vivo and in vitro . The pharmacokinetic processes taking place inside the skin are more complex to elucidate due to the multi-lamellar structure of the skin, heterogeneous distribution of drugs within the tissue, the difficulty of accessing the site of infection complicating sampling and the lack of surrogate markers reflecting the activity of a drug in the skin. This review will discuss the difficulties encountered when investigating drug distribution, PK PD relationships and efficacy in the skin with a focus on cutaneous leishmaniasis treatment.